McDonald’s Beats Pfizer on Growth; Investors Watch Now
As mid-2026 trading picks up, McDonald’s demonstrates stronger growth and cash flow versus Pfizer, which relies on in...
We compare Which Dividend Aristocrats Etf Did Best In 2024, spotlighting performance leaders and factors behind stronger returns.
23,392 articlesAs mid-2026 trading picks up, McDonald’s demonstrates stronger growth and cash flow versus Pfizer, which relies on in...
Oil market swings in early 2026 pushed Exxon Mobil and ConocoPhillips to diverging paths. This piece analyzes who is ...
Transocean (Rig) 2025 earnings could hinge on fleet utilization and day rates. This guide unpackages the drivers, ris...
Risk-off sentiment is weighing on the Nasdaq as tech names retreat. This guide explains what’s moving the stock marke...
As markets swing in early 2026, performing defensive stocks have provided steadier returns, drawing cash into staples...
Pfizer faced big headwinds after its Covid-era peak, but a longer horizon could open doors for outsized returns. Here...
Utilities are no longer safe havens in 2026 as higher yields and climate liabilities challenge traditional income arg...
In a market rattled by softer data, Coca-Cola’s traditional strengths keep drawing new and seasoned investors alike. ...
A long-time investor explains why AbbVie’s mix of rapidly growing immunology drugs and a dependable dividend keeps dr...
Strategy disclosed a new Bitcoin sale as part of its renewed capital plan. Far from signaling weakness, the move coul...
Jim Cramer warned that semiconductor stocks could slide as margin selling weighs on the sector, pointing investors to...
As Sempra wraps up the 2025 fiscal year, investors want clarity on the Q4 2025 earnings trajectory. This article brea...